Could cause temporary or reversible harm; serious harm is unlikely.
Defective container; blister packaging inadequately sealed.
| Brand name | GABAPENTIN |
| Generic name | GABAPENTIN |
| Active ingredient(s) | GABAPENTIN |
| Distributed by / for | MAJOR PHARMACEUTICALS, Indianapolis, IN, 46268 USA, Distributed by Cardinal Health, Dublin, OH 43017 |
| NDC | 55154-3363-0 |
| Full product label | Gabapentin Capsules, USP, 100 mg, 10 capsules (10x1) per bag, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN, 46268 USA, Distributed by Cardinal Health, Dublin, OH 43017, NDC 55154-3363-0 |
| Recalling firm | The Harvard Drug Group LLC |
| Distribution | Nationwide |
| Quantity | 3,527 bags |
| Recall initiated | 2025-06-19 |
| Report date | 2025-07-09 |
| Recall completed | — |
| Recall number | D-0508-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Dublin OH United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗